Navigation Links
Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
Date:3/28/2013

SEATTLE, March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology (still ongoing in the rodent), clinical signs and clinical chemistries. Omeros expects to submit a European Clinical Trial Application (CTA) in the second quarter of this year to initiate clinical trials evaluating OMS721.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, or the acquired immune response to infection. The Company has conducted a series of in vivo studies that suggest that MASP-2 inhibition may have a preventive or therapeutic effect in the treatment of atypical hemolytic uremic syndrome (aHUS), HUS, wet age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), transplant-related complications, ischemia-reperfusion injury, and other immune-related disorders.

The studies reported today in both primates and rodents provide the primary safety data expected to support the initiation of OMS721 clinical studies in mid-year 2013. The pharmacokinetic results in primates demonstrated that subcutaneous administration of OMS721 resulted in maximal inhibition of the lectin pathway within six hours of administration and
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
(Date:7/11/2014)...  Australian drug delivery company, Phosphagenics Limited (ASX: POH; ... million via a placement of A$16.3 million to institutional ... Asia and Australia ... plan (SPP) to be offered to existing shareholders.  The ... tranches. "This capital raising positions us strongly ...
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... NEW YORK, Sept. 22 Amgen and Pfizer today ... Everyday Style and Psoriasis™," an online resource, providing a ... Hosted by Tim Gunn, mentor to the designers on ... Claiborne, Inc. and dermatologist Susan C. Taylor, M.D., the ...
... of Surgery Case Reports -- OXFORD, England, September 22, 2010 ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Medicine Technology:Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis™' Hosted by Tim Gunn 2Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis™' Hosted by Tim Gunn 3Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis™' Hosted by Tim Gunn 4Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis™' Hosted by Tim Gunn 5Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis™' Hosted by Tim Gunn 6Elsevier Launches International Journal of Surgery Case Reports 2Elsevier Launches International Journal of Surgery Case Reports 3Elsevier Launches International Journal of Surgery Case Reports 4Elsevier Launches International Journal of Surgery Case Reports 5Elsevier Launches International Journal of Surgery Case Reports 6Elsevier Launches International Journal of Surgery Case Reports 7Elsevier Launches International Journal of Surgery Case Reports 8Elsevier Launches International Journal of Surgery Case Reports 9
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... during the five years to 2014 on the heels ... of 2010 prompted farmers to dedicate a larger share ... ethanol production. More specifically, the regulations required the mixing ... rapidly expanding biofuel production in the United States created ...
(Date:7/11/2014)... surgery to repair damage to the anterior cruciate ligament (ACL) ... -- could increase a young athlete,s risk for further injuries, ... patients, aged 8 to 16, who had ACL reconstruction surgery. ... after their injury, 37 had surgery six to 12 weeks ... after their injury. The youngsters who had surgery later ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... potential vaccine to protect children from the worldwide scourge of ... children. While the vaccine only prevented dengue fever in ... series of three shots, it protected more than 88 percent ... fever can lead to hospitalization, and sometimes death. "This ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Prostate cancer patients ... receive less effective treatment and die sooner if they ... analyzed data from more than 41,200 American men who ... 2007. They followed them through 2009. Nearly 1,900 of ... two years before their prostate cancer was discovered. ...
(Date:7/11/2014)... Down is a reliable source for cheap Luke Bryan tickets ... years Luke Bryan has been honored by almost every major association ... award shows, but each summer, he hits the road on what ... and this summer is more of the same. When it comes ... success that is currently entitled to Luke Bryan. The native of ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3
... , FORT MYERS, Fla., Dec. 4 NeoGenomics, Inc. ... Jones has been appointed Executive Vice President, Finance and that George ... Mr. Cardoza will be responsible for managing all internal financial affairs ... focus on developing strategic initiatives on behalf of NeoGenomics as well ...
... CITY, Mo., Dec. 4 Farmers Insurance Missouri State Executive Director ... CEO and creator of a children,s fire safety program sponsored by ... a children,s fire safety day at the Missouri Capitol December 9. ... for fire safety comes following a tragic fire that took the ...
... 2009 New findings by UT Southwestern researchers suggest ... might also help slow the destruction of insulin-producing cells ... In type 1 diabetes, formerly known as ... which produce insulin, are destroyed by an autoimmune process. ...
... personality, study finds , FRIDAY, Dec. 4 (HealthDay News) -- ... Facebook, reveal the real you? The odds are good that ... tend to express their true selves instead of idealized identities. ... widely held assumption is that people are using their profiles ...
... ... signed exclusive agreements in 2009 with USA IDN Health Systems and hospitals valued at $22.4 ... the end of 2009. , ... Seattle, WA (PRWEB) December 4, 2009 -- PHACTS, LLC, a leader in Pharmacy Inventory Management ...
... , ORLANDO, Fla., Dec. 4 , ,What: ... health benefits provider, is introducing Dancetown, ... video game at its Kissimmee Guidance Center on Tues., ... event, which is, free and open ...
Cached Medicine News:Health News:NeoGenomics Announces Executive Appointments 2Health News:Missouri Safety Day at the Capitol 2Health News:FDA-approved drug may slow beta cell destruction in type 1 diabetes patients 2Health News:Online Identities Likely to Match Reality 2Health News:PHACTS Receives $22.4 Million in New Business Commitments 2Health News:Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee 2
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
...
Medicine Products: